Immunovia AB 2020 AR2
The report highlights Immunovia's progress in 2020, particularly the completion of the verification study for its blood test IMMray™ PanCan-d, which showed 99% specificity and 78% sensitivity for early-stage pancreatic cancer. Despite challenges from the COVID-19 pandemic, which temporarily closed its Marlborough laboratory and delayed the product launch, the company successfully raised approximately SEK 400 million through a directed share issue to fund commercialization. Additionally, Immunovia appointed Patrik Dahlen as its new CEO and continued its three major prospective clinical studies involving over 10,000 individuals. The company also published its statutory sustainability report focusing on public welfare, sustainable products, and maintaining a diverse and equal workplace.
Company: Immunovia AB
Sector: Professional & technical services
Country: Sweden
Year: 2020
Type: AR2
Pages: 77
Back to company
Immunovia AB
Annual Report
The report highlights Immunovia's progress in 2020, particularly the completion of the verification study for its blood test IMMray™ PanCan-d, which showed 99% specificity and 78% sensitivity for early-stage pancreatic cancer. Despite challenges from the COVID-19 pandemic, which temporarily closed its Marlborough laboratory and delayed the product launch, the company successfully raised approximately SEK 400 million through a directed share issue to fund commercialization. Additionally, Immunovia appointed Patrik Dahlen as its new CEO and continued its three major prospective clinical studies involving over 10,000 individuals. The company also published its statutory sustainability report focusing on public welfare, sustainable products, and maintaining a diverse and equal workplace.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Published
Mar 12, 2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees